KI-Chat
Loading data for DERM — first visit, this takes a few seconds.

Journey Medical Corporation

DERM · NasdaqCM · USD

7.23 +0.14 (1.97%)

Zum Schluss: Sep 11, 2026, 3:59 PM

Volumen
168K

Journey Medical Corporation (DERM) Aktienkurs, Analyse & Daten

Innerer Wert

Innerer Wert wird geladen…

Analystenprognose

Aktienprognosen →

Analystenprognose nicht verfügbar

12-Monats-Kursziel · n/a Analysten

Analysten-Konsens: n/a

Intervall:1D
Kerzen und Signale werden geladen…

Finanzielle Entwicklung

Finanzdaten ansehen →
Umsatz (TTM)
$68.18M

Lädt...

Letzte Ergebnisse

GemeldetVs. SchätzungYoY-Veränderung
Umsatz$15.96Mn/a+21.48%
EPS-$0.01+$0.01+93.75%

Nächste Ergebnisse

während der Handelszeiten.

Schätzung · Upgrade →

Ergebnisdetails →

Kennzahlen

Geld
5.17
Nettogewinn (TTM)
-6.1M
1.10
-0.22
n/a
-120.5
KBV (TTM)
6.23
KUV (TTM)
2.99
Termin Quartalszahlen
Nov 11, 2026
Brief
9.24
Volumen
167,997
Ø Vol. (20D)
242,456
Eröffnung
7.18
Vortagesschluss
7.09
Tagesspanne
7.06 - 7.41
52-Wk Range
4.31 - 9.55
Ex-Dividenden-Datum
n/a

Über Journey Medical Corporation

Profil ansehen →
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Drug Manufacturers - Specialty & Generic · Healthcare

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Sektor Healthcare
IPO Datum Nov 12, 2021
Mitarbeiter 58
Börse NasdaqCM
Tickersymbol DERM